Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance

Damora Therapeutics, Inc.

Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.
Received 180-day extension until September 22, 2024 to regain $1.00 minimum bid price compliance.
Company had failed to meet bid price requirement by March 25, 2024 compliance date.
GLTO continues trading under same symbol; reverse stock split is under consideration.
If not compliant by September 22, Nasdaq may delist; company could appeal to hearings panel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.